Quarterly report pursuant to Section 13 or 15(d)

Revenue Recognition - Narrative (Details)

v3.20.1
Revenue Recognition - Narrative (Details) - USD ($)
3 Months Ended 30 Months Ended 63 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Mar. 31, 2020
Mar. 31, 2020
Dec. 31, 2019
Disaggregation of Revenue [Line Items]          
Prior period performance obligation revenue recognized $ 8,900,000 $ 8,400,000      
Overpayment reimbursement liability 23,500,000   $ 23,500,000 $ 23,500,000 $ 27,300,000
Revenue recognized     0    
Total revenues 211,466,000 222,451,000      
Contract liability 12,300,000   12,300,000 12,300,000 $ 21,800,000
Rayaldee          
Disaggregation of Revenue [Line Items]          
Revenue recognized 9,900,000 5,800,000      
Total revenues 22,683,000        
Transfer of intellectual property and other          
Disaggregation of Revenue [Line Items]          
Total revenues 9,553,000 18,259,000      
Pfizer | Products          
Disaggregation of Revenue [Line Items]          
Revenue recognized       0  
Contract liability 7,500,000   $ 7,500,000 $ 7,500,000  
Pfizer | Products | Transfer of intellectual property and other          
Disaggregation of Revenue [Line Items]          
Total revenues $ 8,700,000 $ 17,400,000